Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Schedule of customers representing greater than 10% of revenues/accounts receivable balances

The following table sets forth customers who represented 10% or more of our total revenues for 2018, 2017 and 2016:



	Years Ended December 31,
	2018	2017	2016
AmerisourceBergen Drug Corporation	27%	26%	27%
McKesson Corporation	26%	24%	14%
Caremark, LLC	< 10%	< 10%	10%

Schedule of property and equipment estimated useful lives

Property and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:



	Useful Life
Computer equipment and software	5 Years
Furniture and fixtures	5 Years
Leasehold improvements	Lesser of Lease or Asset Life
Laboratory and production equipment	5 Years / 8 Years

Property and equipment, net consisted of the following as of December 31, 2018 and 2017 (in thousands):



	December 31,
	2018			2017
Computer equipment and software	$	1,637		$	1,401
Furniture and fixtures	1,737			1,442
Leasehold improvements	2,938			2,938
Laboratory and production equipment	6,000			654
Construction in progress	420			5,068
	12,732			11,503
Less: accumulated depreciation	(5,211		)	(3,599		)
Property and equipment, net	$	7,521		$	7,904

Schedule of components of basic and diluted net income (loss) per share

The components of basic and diluted net (loss) income per share for 2018, 2017 and 2016 were as follows (in thousands, except per share data):



	Years Ended December 31,
	2018			2017			2016
Net (loss) income from continuing operations	$	(169,339	)	$	(205,153	)	$	2,093
Net income (loss) from discontinued operations	103,578			5,925			(4,576		)

Weighted average common shares outstanding	34,394			34,907			34,346
Effect of dilutive securities:
Stock options and RSUs	—			—			487
Shares used in calculating dilutive net loss per share	34,394			34,907			34,833

Basic net (loss) income per share:
(Loss) income from continuing operations	$	(4.92	)	$	(5.88	)	$	0.06
Income (loss) from discontinued operations	3.01			0.17			(0.13		)
Total	$	(1.91	)	$	(5.71	)	$	(0.07	)

Diluted net (loss) income per share:
(Loss) income from continuing operations	$	(4.92	)	$	(5.88	)	$	0.06
Income (loss) from discontinued operations	3.01			0.17			(0.13		)
Total	$	(1.91	)	$	(5.71	)	$	(0.07	)

Schedule of anti-dilutive securities from computation of diluted net (loss) income per share

The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the purchase of shares under our employee stock purchase plan, the vesting of RSUs, the exercise of warrants (prior to consideration of the treasury stock method), and the conversion of the Convertible Notes, which were excluded from our computation of diluted net (loss) income per share because their inclusion would have been anti-dilutive (in thousands):



	Years Ended December 31,
	2018	2017		2016
Options to purchase shares of common stock	3,797	3,531		2,590
Shares of common stock issuable upon the vesting of RSUs	1,129	1,070		613
Warrants	1,008	1,008		7,382
2022 Convertible Notes	11,695	11,695		—
2019 Convertible Notes	790	790		7,382
Shares of common stock under employee stock purchase plan	81	—	—	36
Total	18,500	18,094		18,003